The closing price of ADMA Biologics Inc. (NASDAQ: ADMA) was 2.62 for the day, up 1.16% from the previous closing price of $2.59. In other words, the price has increased by $+0.0300 from its previous closing price. On the day, 2744704 shares were traded. ADMA reached its highest trading level at $2.6450 during the session, while it also had its lowest trading level at $2.5600.
Our analysis of ADMA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.70 and its Current Ratio is at 7.90. In the meantime, Its Debt-to-Equity ratio is 1.22 whereas as Long-Term Debt/Eq ratio is at 1.22.
Upgrades & Downgrades
On November 09, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $4.50.
On June 04, 2019, Jefferies started tracking the stock assigning a Buy rating and target price of $8.Jefferies initiated its Buy rating on June 04, 2019, with a $8 target price.
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 25 when Grossman Adam S bought 250,000 shares for $1.00 per share. The transaction valued at 250,000 led to the insider holds 1,128,444 shares of the business.
Grossman Adam S bought 100,000 shares of ADMA for $100,000 on Oct 25. The President and CEO now owns 2,137,616 shares after completing the transaction at $1.00 per share. On Oct 25, another insider, LENZ BRIAN, who serves as the EVP, CFO of the company, bought 30,000 shares for $1.00 each. As a result, the insider paid 30,000 and bolstered with 1,065,501 shares of the company.
For the stock, the TTM Price-to-Sale (P/S) ratio is 4.78 while its Price-to-Book (P/B) ratio in mrq is 4.52.
Stock Price History:
Over the past 52 weeks, ADMA has reached a high of $2.92, while it has fallen to a 52-week low of $1.01. The 50-Day Moving Average of the stock is 2.4220, while the 200-Day Moving Average is calculated to be 1.8944.
ADMA traded an average of 2.91M shares per day over the past three months and 3.79M shares per day over the past ten days. A total of 196.35M shares are outstanding, with a floating share count of 175.65M. Insiders hold about 1.70% of the company’s shares, while institutions hold 74.80% stake in the company. Shares short for ADMA as of Jul 14, 2022 were 28.73M with a Short Ratio of 9.10, compared to 25.54M on Jun 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 14.63% and a Short% of Float of 15.24%.
The firm’s stock currently is rated by 3 analysts. On average, analysts expect EPS of $-0.08 for the current quarter, with a high estimate of $-0.07 and a low estimate of $-0.09, while EPS last year was $-0.14. The consensus estimate for the next quarter is $-0.07, with high estimates of $-0.06 and low estimates of $-0.08.
Analysts are recommending an EPS of between $-0.31 and $-0.37 for the fiscal current year, implying an average EPS of $-0.33. EPS for the following year is $-0.17, with 3 analysts recommending between $-0.14 and $-0.21.
It is expected that $90B in revenue will be generated in the current quarter, according to 3 analysts. It ranges from a high estimate of $33.1M to a low estimate of $30.3M. As of the current estimate, ADMA Biologics Inc.’s year-ago sales were $17.83M, an estimated increase of 78.40% from the year-ago figure.
A total of 3 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $137.7M, while the lowest revenue estimate was $128.8M, resulting in an average revenue estimate of $131.92M. In the same quarter a year ago, actual revenue was $80.94M, up 63.00% from the average estimate. Based on 3 analysts’ estimates, the company’s revenue will be $192.68M in the next fiscal year. The high estimate is $216M and the low estimate is $173.9M. The average revenue growth estimate for next year is up 46.10% from the average revenue estimate for this year.